495 related articles for article (PubMed ID: 14671429)
1. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kucukercan M; Ceran N
Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
[TBL] [Abstract][Full Text] [Related]
2.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
3. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Burgess DS; Nathisuwan S
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):35-41. PubMed ID: 12376029
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
5. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
[TBL] [Abstract][Full Text] [Related]
8. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
[TBL] [Abstract][Full Text] [Related]
10. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
[TBL] [Abstract][Full Text] [Related]
11. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
[TBL] [Abstract][Full Text] [Related]
15. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
Metan G; Zarakolu P; Hasçelik G; Akova M
Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
[TBL] [Abstract][Full Text] [Related]
16.
Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK; Kuti JL; Nicolau DP
Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
Dawis MA; Isenberg HD; France KA; Jenkins SG
J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
[TBL] [Abstract][Full Text] [Related]
19. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Jones RN; Stilwell MG; Rhomberg PR; Sader HS
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
[TBL] [Abstract][Full Text] [Related]
20. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
Dundar D; Otkun M
Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]